INTRODUCTION
(IROX) can also be administered together with/ without 5-FU/LV to mCC patients [1] . These primary treatments help to palliate symptoms and prolong survival. The recommended management strategies are based on evidence from randomized clinical trials (RCTs) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
However, real-world benefit of Tx2 among elderly mCC patients who have multiple comorbidities may differ from those enrolled in RCTs. Furthermore, a large portion of elderly mCC patients who receive Tx1 may not receive Tx2 or subsequent treatment line (TxS) due to multiple comorbid conditions, tumor responses, and severe side effects [12, 13] . Retrospective cohort studies are useful to assess the effectiveness of Tx2 as compared to Tx1 for mCC, which provides complementary information to those obtained from RCTs to improve clinical practices to 'real world' patients, especially populations not studied in RCTs.
Given the rising cost of oncology care, the survival benefit and incremental cost associated with Tx2 for elderly mCC patients are particularly relevant to payers, such as Medicare. Moreover, the real-world survival benefit of Tx2, overall cost and costeffectiveness of Tx2 can also help clinicians to communicate with patients more efficiently and help patients make informed decisions regarding their treatment.
METHODS

Data
The surveillance epidemiology and end results 
Inclusion and Exclusion Criteria
The study population consisted of SEERMedicare enrollees (aged C66 years at the 
Identification of Treatment Lines and Associated Costs
The algorithm used for identifying treatment lines was developed by Bikov et al. [14] , which is a claim-based algorithm used to identify initial and subsequent treatment lines. This study adopted the Medicare system perspective in the cost analysis and included direct medical costs reimbursed under Medicare Parts A and B, i.e., drug costs, hospitalization costs and physician fees.
Patient-Level Factors Included in the Survival and Cost Analyses
Patient-level clinical variables included poorly graded tumor, surgery of primary site, and surgery of liver metastases. Indicators were created for poorly graded tumor and surgery of primary site, respectively. A categorical variable was created for surgery of liver metastases: (1) none; (2) surgery to other sites; and (3) ablation of liver metastases with/out surgery to other sites. Charlson comorbidity index (CCI) was measured using claims within 1 year prior to cancer diagnosis [15, 16] . A proxy for poor performance status was created to detect any hospital bed use, oxygen use, walking aid use or wheel chair use within 3 months prior to cancer diagnosis [17] . Patient demographic information such as age, gender, marital status, urban living status, and race/ethnicity were also included in regression analyses. Age was defined as a categorical variable (each 10-year increment in age at the time of diagnosis). Race/ethnicity was categorized into Non-Hispanic White, African American, Hispanic White, and Asian. Contextual variables, i.e., indicators for year of diagnosis (2003) (2004) (2005) (2006) (2007) and the SEER registry sites were also included in the analyses.
Statistical Methods
Patient-level factors were examined by the number of chemotherapy/biologics treatment lines: no treatment (Tx); Tx1 only; or Tx2, which included those who received two or more lines. The column distributions of each patient-level factor for the Tx1 only group and the Tx2 group were compared with the no Tx group. In this unadjusted analysis, p values were generated to measure the statistical differences between the corresponding column percentages, where the no Tx group was the reference group.
Because there is a sequential ordering from Tx1 to Tx2, on average patients who received Tx2 lived longer than those who received Tx1 only. A time-varying Cox regression framework was used to examine the incremental survival benefit associated with Tx2 to address this ''immortal time bias'' [18] . The time-varying modeling approach assigned a patient in the 'control' group during the time period of Tx1 and switched her/him to the 'experiment' group at the time of initiation of Tx2. As compared with the static modeling approach, where patients were categorized into two groups according to their final treatment status (received Tx1 only versus Tx2), the timevarying modeling approach took the dynamic process of patients' change of treatment status into consideration, which reduced the bias of the survival benefit associated with Tx2. We conducted both static and time-varying modeling approaches and compared the survival benefits associated with Tx2 using the Cox regression framework.
Individual mCC patients had different probabilities of receiving treatment(s) according to a specific set of patient-level clinical and demographic variables. The inverse probability weighting (IPW) method was used to control for the self-selection issue into treatment(s).
Multivariate sequential logistic regressions were utilized to estimate individual patients' probabilities of receiving Tx1, Tx2 and TxS, respectively. Two more variables were added in this step: (1) state buy-in status, which is indicative of low socioeconomic status; and (2) household median income, which measures the income level of the neighborhood defined by the zip code of the patient's residence. We used this variable as an additional proxy for patients' socioeconomic status, as has been done in prior studies [19] . The combination of the timevarying Cox regression framework and IPW method offered a flexible framework, where individual patients' IPW weights were updated depending on their treatment status, e.g., switching from Tx1 to Tx2.
Patients were also subject to censoring over time. Each month, a certain percentage of identified mCC patients were censored either due to end of study or switching to a health maintenance organization plan. The Lin's regression method was proposed to reduce the bias due to patients' missing information of their future cost accumulation elsewhere [20] . This method inflates the costs of those patients who are still alive and uncensored proportionally to the percentage of patients who are censored during each month. The monthly incremental cost associated with Tx2 was obtained by a multivariate regression, which measures the difference in costs of patients who were actively in Tx2 with those who were actively in Tx1. The overall incremental cost of Tx2 over the 5-year period was the sum of all 60 monthly costs that could be attributed to Tx2 versus Tx1 [21] . An elderly mCC patient would be in the 'control' group (Tx1 group) and switched to the comparison group (i.e., Tx2 group) later on according to the treatment status in a particular month.
Therefore, the cost analysis of Tx2 is also time varying in essence. The incremental costeffectiveness ratio (ICER) was created by the ratio of overall incremental cost and survival benefits associated with Tx2.
The static modeling of the incremental cost associated with Tx2 was obtained by comparing the Tx2 group with the Tx1 only group according to their final treatment status. Similar multivariate regressions were conducted as in the time-varying approach; however, the control group and comparison group remained unchanged over time. The corresponding ICER of the static modeling was also generated. Both time-varying and static modeling approaches used bootstrapping method to generate the 95% confidence intervals (CI) for the ICERs [22] . We assumed that there is a positive rate of time preference that patients would like to postpone cost in the future, thus separate analyses were conducted to discount the cost at 3 and 5% annually to year 2010 dollars [23] . The statistical significance level was set a priori at a = 0.05.
RESULTS
As shown in Fig. 1 
DISCUSSION
Our study examined the overall costeffectiveness of second-line chemotherapy among real-world elderly mCC patients. Given the enriched and complex chemotherapy treatment options available to mCC patients, it would have been difficult to recruit and randomize a large number of patients into different treatment strategies using a clinical trial approach. Our retrospective study adopted the IPW method and time-varying Cox regression framework to reduce bias due to patients' selection into treatment. Combined with the time-varying cost analysis, our paper provides an ICER for Tx2 among elderly mCC patients, which can facilitate the planning and management of chemotherapy and biologics treatments.
A review study summarized the evidence of survival benefit of different regimens in Tx2 from RCTs [24] . A number of conclusions were made regarding the best treatment options after various initial treatments: Tx2 with active regents was superior to best supportive care; following 5-FU failure, IROX was superior to IRI; 
